{'fraction_non_alphanumeric': 0.038314176245210725, 'fraction_numerical': 0.01532567049808429, 'mean_word_length': 5.371951219512195, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Antibiotics maker Melinta declares bankruptcy

Melinta Therapeutics, a drugmaker in Morristown, New Jersey, that calls itself “the largest pure-play antibiotics company,” has filed for bankruptcy. It’s yet another grim development in the antibiotics industry, which continues to suffer setbacks as big pharma firms shutter their antibiotics divisions and smaller firms struggle to stay afloat. Melinta sells four antibiotics: Baxdela (delafloxacin), Orbactiv (oritavancin), Minocin (minocycline), and Vabomere (meropenem and vaborbactam). In the first 9 months of 2019, Melinta posted $41 million in sales, up 29% from the same period in 2018, largely because of higher sales of Baxdela and Vabomere. Yet the firm had also amassed nearly $1 billion in debt as of Sept. 30. Some of it stems from loans Melinta took on to buy The Medicines Company’s infectious disease business, which included Orbactiv, Minocin, and Vabomere. Melinta warned investors of its potential demise in its last quarterly report and forecast “significant losses” for the